-
1دورية أكاديمية
المؤلفون: Tuğçe Arıcan, Raymond Veldhuis, Luuk Spreeuwers, Loïc Bergeron, Christoph Busch, Ehsaneddin Jalilian, Christof Kauba, Simon Kirchgasser, Sébastien Marcel, Bernhard Prommegger, Kiran Raja, Raghavendra Ramachandra, Andreas Uhl
الوصف: Finger vein recognition is gaining popularity in the field of biometrics, yet the inter-operability of finger vein patterns has received limited attention. This study aims to fill this gap by introducing a cross-device finger vein dataset and evaluating the performance of finger vein recognition across devices using a classical method, a convolutional neural network, and our proposed patch-based convolutional auto-encoder (CAE). The findings emphasise the importance of standardisation of finger vein recognition, similar to that of fingerprints or irises, crucial for achieving inter-operability. Despite the inherent challenges of cross-device recognition, the proposed CAE architecture in this study demonstrates promising results in finger vein recognition, particularly in the context of cross-device comparisons.
-
2دورية أكاديمية
المؤلفون: Eric Hachulla, Gwendal Le Masson, Guilhem Solé, Mohamed Hamidou, Claude Desnuelle, Jean-Philippe Azulay, Gérard Besson, Laure Swiader, Sébastien Abad, Jean-Christophe Antoine, Françoise Bouhour, Alain Créange, Marike Grenouillet, Laurent Magy, Sébastien Marcel, Jean-Michel Paquet, François Rouhart, François Ziegler, Stéphane Mathis, Marc Gauthier-Darnis, Sophie Puget
مصطلحات موضوعية: Pharmaceutics
الوصف: The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Tegeline, an IVIg from LFB Biomedicaments, and assess its safety at home, compared to in hospital, in patients with AID. The included patients were at least 18 years old, suffering from AID, and treated with at least 1 cycle of Tegeline at home after receiving 3 consecutive cycles of hospital-based treatment with Tegeline at a dose between 1 and 2 g/kg/cycle. Forty-six patients with AID, in most cases immune-mediated neuropathies, received a total of 138 cycles of Tegeline in hospital and then 323 at home. Forty-five drug-related adverse events occurred in 17 patients who received their cycles at home compared to 24 adverse events in hospital in 15 patients. Serious adverse events occurred in 3 patients during home treatment, but they were not life-threatening and did not lead to discontinuation of Tegeline. Forty-five patients continued their treatment with Tegeline at home or in hospital; 39 (84.8%) were still receiving home treatment at the end of the study. In conclusion, the study demonstrates the good safety profile of Tegeline administered at home at high doses in patients with AID who are eligible for home administration of Tegeline.
